Chiesi México company information, Employees & Contact Information

FDA Accepts NDA for Chiesi’s Single Inhaler Triple Therapy for Asthma HCPLive

Chiesi buys into Arbor gene editing drug for rare kidney disease BioPharma Dive

Chiesi fertilizes Arbor's rare disease gene therapy efforts with $2B biobucks deal Fierce Biotech

Chiesi, Arbor Target Rare Liver Diseases in Up-to-$2.1B Gene Editing Collaboration Genetic Engineering and Biotechnology News

Chiesi, Arbor Weave $2.1B Rare Disease Pact BioSpace

Samay partners with Chiesi one year after winning MedTech Innovator MassDevice

Chiesi Group and Arbor Biotechnologies Announce a Global GlobeNewswire

Italy's Chiesi Group plans acquisitions to boost sales to 6 billion euros by 2030 Reuters

Italy’s Chiesi Raises Annual Guidance on Drug Sales Growth Bloomberg.com

Chiesi, Viatris among collaborators on BIO's latest BBC-produced video series Fierce Pharma

Rare disease research boost for lysosomal scientists backed by Chiesi Euractiv

Chiesi Group partners Arbor on gene editing programmes Pharmaceutical Technology

Europe's rare disease innovation progress at risk, warns senior Chiesi executive Euractiv

Chiesi Global Rare Diseases Announces Multiple Presentations at 21st Annual WORLDSymposium™ Research Meeting PR Newswire

Chiesi’s Rare Disease Strategy Expands to Genetic Meds via Alliance With CRISPR Startup Arbor MedCity News

Chiesi collaborates with Serna Bio on respiratory diseases The Pharma Letter

Chiesi and Arbor ink gene editing deal The Pharma Letter

Chiesi Global Rare Diseases Announces Co-Development Agreement with Aliada Therapeutics to Advance Blood-Brain Barrier-Crossing Platform Technology in Lysosomal Storage Disorders PR Newswire

Chiesi accelerates sustainable growth in 1st-half 2025 The Pharma Letter

Chiesi enters deal to leverage Key2Brain’s technology The Pharma Letter

Chiesi buys into Gossamer's Winrevair rival, betting almost $500M Fierce Biotech

Improving the impact of inhalers BBC

chiesi group opens healthcare innovation regeneration in parma, italy Designboom

Chiesi acquires Amryt pharma to boost rare disease therapy focus drugdiscoverytrends.com

Chiesi offers Affibody breath of fresh air in respiratory disease deal worth up to $637M Fierce Biotech

Chiesi Farmaceutici Headquarters Arup

Disrupters: Giacomo Chiesi Pharma Voice

Chiesi survey shows how Fabry drugs are failing patients, providing road map for ousting incumbents Fierce Pharma

JPM23: Chiesi gets jump-start on JPM buzz with $1.48B Amryt buyout Fierce Pharma

Chiesi Inks Potential $486M Deal with Gossamer Bio for Blood Pressure Treatment BioSpace

Santhera fully divests rare eye disease drug Raxone to Chiesi Pharmaceutical Technology

Chiesi Ups Rare Disease Game with $1.48B Amryt Acquisition BioSpace

Chiesi study aims to quantify economic benefits of rare disease drugs Fierce Pharma

DKSH and Chiesi Asian progress ‘a new precedent’ for rare disease approvals The Pharma Letter

After Amryt buyout, Chiesi scores with FDA nod for rare skin disease treatment Filsuvez Fierce Pharma

Chiesi and Gossamer collaborate to develop drug to treat respiratory diseases PharmaTimes

Arbor Bio in $2B+ deal with Chiesi for gene editing therapies BioWorld MedTech

Chiesi Group invests €400m to establish biotech centre of excellence in Italy PMLiVE

Arbor, Chiesi reach gene editing deal worth up to $2B PharmaLive

Chiesi Group announces performance growth in 2020 GlobeNewswire

Chiesi creates Boston rare disease unit ahead of Fabry launch Fierce Biotech

Chiesi Rare Skin Disease Drug Acquired in Billion Dollar Deal Wins FDA Approval MedCity News

Chiesi Farmaceutici agrees to buy Amryt Pharma for $1.48bn Pharmaceutical Technology

Chiesi report highlights incorrect inhaler use among UK asthma patients PMLiVE

Chiesi, buffing up environmental credentials, works with BBC to spread message about greener inhalers Fierce Pharma

Chiesi Moves Into Rare Disease Gene Therapy Under Pact With Arbor Citeline News & Insights

Chiesi Global Rare Diseases Announces FDA Approval of FERRIPROX® (deferiprone) for Treatment of Transfusional Iron Overload due to Sickle Cell Disease PR Newswire

Chiesi dumps uniQure’s hemophilia B gene therapy Fierce Biotech

Better Practices Lead to Greater Profits Mexico Business News

Chiesi Farmaceutici completes acquisition of Amryt Pharma Indian Pharma Post

Patricia Chiesi Obituary (2011) - Royal Oak, MI - Saginaw News on MLive.com MLive.com

Chiesi reprimanded again over Fostair drug Pharmafile

Former beauty queen Chiesi sentenced to 30 months in insider-dealing trial The Guardian

Danielle Chiesi Is Back Dealbreaker